Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

<p>Pixium Vision is developing two different retinal implants that provide vision by electrically stimulating the retina. Commercialisation efforts for Iris II are starting in Europe. Prima intends to target a larger population, and human trials could start in H117. Using a risk-adjusted NPV model, we obtain a pipeline rNPV of &euro;131.4m, up from &euro;125.5m, previously.</p>

Pixium Vision is developing two different retinal implants that provide vision by electrically stimulating the retina. Commercialisation efforts for Iris II are starting in Europe. Prima intends to target a larger population, and human trials could start in H117. Using a risk-adjusted NPV model, we obtain a pipeline rNPV of &euro;131.4m, up from &euro;125.5m, previously.

Key advancements for Iris II and Prima in 2017

<p>Pixium announced this week that it has completed the 10th and final implantation as part of its ongoing European Iris-II study. This trial began in January 2016 and will assess the Iris II epi-retinal implant in patients with retinitis pigmentosa (RP) and certain other retinal dystrophies. While the study will assess the device for at least 18 months, interim data could be available in mid-2017 and would support reimbursement applications in European countries such as the UK, France and Germany.</p>

Pixium announced this week that it has completed the 10th and final implantation as part of its ongoing European Iris-II study. This trial began in January 2016 and will assess the Iris II epi-retinal implant in patients with retinitis pigmentosa (RP) and certain other retinal dystrophies. While the study will assess the device for at least 18 months, interim data could be available in mid-2017 and would support reimbursement applications in European countries such as the UK, France and Germany.

Pixium completes 10th implantation of Iris II study

France

Pixium Vision SA develops retinal implant systems. The Company develops epi-retinal and sub-retinal implant systems to treat patients who have lost their sight, with the intention of improving their vision and enabling them to lead more independent lives. Pixium Vision markets its systems throughout Europe.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pixium Vision Sa (PIX FP)

Key advancements for Iris II and Prima in 2017

Pixium Vision is developing two different retinal implants that provide vision by electrically stimulating the retina. Commercialisation efforts...

Edison Investment Research

Pixium completes 10th implantation of Iris II study

Pixium announced this week that it has completed the 10th and final implantation as part of its ongoing European Iris-II study. This trial began in...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)